ADC Therapeutics director granted 45K shares

ADC Therapeutics SA director Viviane Monges reported routine equity compensation and related tax withholding.

Rhea-AI Filing Summary

ADC Therapeutics SA director Viviane Monges reported routine equity compensation and related tax withholding. She was granted 45,000 restricted stock units for her service as a director under the company’s 2019 Equity Incentive Plan, with each unit representing one common share.

In a separate transaction tied to the vesting of previously granted restricted share units, 2,596 common shares were withheld by the company to satisfy her tax withholding obligations at a price of $3.08 per share. After these transactions, she directly owns 186,447 common shares. These events reflect compensation and tax mechanics, not open-market share purchases or sales.

Insider Trade Summary

2 transactions reported

Mixed 2 txns

Insider Monges Viviane

Role Director

Type	Security	Shares	Price	Value
Exercise Price or Tax Liability	Common Shares	2,596	$3.08	$8K
Grant/Award	Common Shares	45,000	$0.00	$0.00

Holdings After Transaction: Common Shares — 186,447 shares (Direct)

Footnotes (2)

1. F1. Represents the annual grant of restricted stock units ("RSUs") made under the Issuer's 2019 Equity Incentive Plan for service as a Director. The RSUs vest on the earlier of (i) one year from the grant date or (ii) the date of the 2027 Annual Meeting of Shareholders, subject to the Reporting Person's continued service to the Issuer. Each RSU represents a contingent right to receive one share of the Issuer's common stock.
2. F2. Represents the number of Common Shares withheld by the Issuer to satisfy the Reporting Person's tax withholding obligations in connection with the vesting of restricted share units previously granted.

Key Figures

RSU grant: 45,000 units Tax withholding shares: 2,596 shares Withholding price: $3.08 per share +3 more

6 metrics

RSU grant 45,000 units Annual director grant under 2019 Equity Incentive Plan

Tax withholding shares 2,596 shares Withheld to satisfy tax obligations on RSU vesting

Withholding price $3.08 per share Value used for shares withheld for taxes

Shares owned after transactions 186,447 shares Direct common share ownership following reported transactions

Tax withholding count 1 transaction F-code disposition for tax obligations

Grant/acquisition count 1 transaction A-code grant or award acquisition

Key Terms

restricted stock units, 2019 Equity Incentive Plan, tax withholding obligations, grant, award, or other acquisition, +1 more

5 terms

restricted stock units financial

"Represents the annual grant of restricted stock units ("RSUs") made under the Issuer's 2019 Equity Incentive Plan"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

2019 Equity Incentive Plan financial

"annual grant of restricted stock units ("RSUs") made under the Issuer's 2019 Equity Incentive Plan for service as a Director"

tax withholding obligations financial

"Common Shares withheld by the Issuer to satisfy the Reporting Person's tax withholding obligations in connection with the vesting of restricted share units"

grant, award, or other acquisition financial

"transaction code description: Grant, award, or other acquisition"

Payment of exercise price or tax liability by delivering securities financial

"transaction code description: Payment of exercise price or tax liability by delivering securities"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transactions did ADC Therapeutics (ADCT) report for Viviane Monges?

ADC Therapeutics reported that director Viviane Monges received a grant of 45,000 restricted stock units and had 2,596 common shares withheld to cover tax obligations from prior RSU vesting, leaving her with 186,447 common shares owned directly.

How many ADC Therapeutics (ADCT) shares were granted to director Viviane Monges?

Viviane Monges received an annual grant of 45,000 restricted stock units for her service as a director. Each RSU represents a contingent right to receive one common share under ADC Therapeutics’ 2019 Equity Incentive Plan, with vesting tied to future board service.

Why were 2,596 ADC Therapeutics (ADCT) shares disposed of in this Form 4?

The 2,596 ADC Therapeutics common shares were withheld by the company to satisfy Viviane Monges’ tax withholding obligations on vesting of earlier RSU awards. This F-code transaction reflects tax payment mechanics, not an open-market sale initiated by the director.

What are Viviane Monges’ ADC Therapeutics (ADCT) holdings after these transactions?

Following the reported RSU grant and tax-related share withholding, Viviane Monges directly owns 186,447 ADC Therapeutics common shares. The Form 4 indicates these are held as direct ownership, reflecting her ongoing equity stake as a member of the board.

How do the RSUs granted to ADC Therapeutics (ADCT) director Viviane Monges vest?

The RSUs granted to Viviane Monges vest on the earlier of one year from the grant date or the date of ADC Therapeutics’ 2027 Annual Meeting of Shareholders, provided she continues serving as a director. Each vested RSU converts into one common share.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/03/2026 - 05:03 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Monges Viviane

(Last) (First) (Middle)

430 MOUNTAIN AVENUE, SUITE 404

(Street)

NEW PROVIDENCE NEW JERSEY 07974

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
ADC Therapeutics SA [ ADCT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/01/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Shares	06/01/2026		A		45,000(1)	A	$0	189,043	D
Common Shares	06/03/2026		F(2)		2,596	D	$3.08	186,447	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents the annual grant of restricted stock units ("RSUs") made under the Issuer's 2019 Equity Incentive Plan for service as a Director. The RSUs vest on the earlier of (i) one year from the grant date or (ii) the date of the 2027 Annual Meeting of Shareholders, subject to the Reporting Person's continued service to the Issuer. Each RSU represents a contingent right to receive one share of the Issuer's common stock.

2. Represents the number of Common Shares withheld by the Issuer to satisfy the Reporting Person's tax withholding obligations in connection with the vesting of restricted share units previously granted.

Remarks:

	/s/ Lisa Kallebo, as Attorney-in-Fact for Viviane Monges	06/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)